Adam III - Nexgel Chief Officer
| NXGL Stock | USD 3.32 0.09 2.79% |
Insider
Adam III is Chief Officer of Nexgel Inc
| Age | 47 |
| Address | 2150 Cabot Boulevard West, Langhorne, PA, United States, 19047 |
| Phone | 215 702 8550 |
| Web | https://nexgel.com |
Nexgel Management Efficiency
The company has return on total asset (ROA) of (0.2316) % which means that it has lost $0.2316 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6431) %, meaning that it created substantial loss on money invested by shareholders. Nexgel's management efficiency ratios could be used to measure how well Nexgel manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.39. The value of Return On Capital Employed is expected to slide to -0.49. At this time, Nexgel's Intangible Assets are quite stable compared to the past year. Debt To Assets is expected to rise to 0.13 this year, although the value of Total Current Assets will most likely fall to about 3.9 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| David BA | GlucoTrack | 59 | |
| Julia Kirshner | Predictive Oncology | N/A | |
| Olivier Taelman | Nyxoah | 53 | |
| Robert Hayes | Sharps Technology | 57 | |
| Robert Myers | Predictive Oncology | 67 | |
| Esq CPA | GlucoTrack | 59 | |
| MScEE MBA | GlucoTrack | 70 | |
| BS BSc | Predictive Oncology | 73 | |
| Steven MD | Sharps Technology | 62 | |
| Robert MBA | Nyxoah | 77 | |
| Theresa Ferguson | Predictive Oncology | N/A | |
| Dorit Nahari | Nyxoah | N/A | |
| Raymond Vennare | Predictive Oncology | 71 | |
| DSc OD | Predictive Oncology | N/A | |
| Bruno Onkelinx | Nyxoah | N/A | |
| Barry Berler | Sharps Technology | 70 | |
| Alan Blackman | Sharps Technology | 75 | |
| Keisha Harcum | Milestone Scientific | N/A | |
| Robert MBA | Predictive Oncology | 69 | |
| CPA CPA | Daxor | 65 | |
| Joy Goudie | Daxor | N/A | |
Management Performance
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.23 |
Nexgel Inc Leadership Team
Elected by the shareholders, the Nexgel's board of directors comprises two types of representatives: Nexgel inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nexgel. The board's role is to monitor Nexgel's management team and ensure that shareholders' interests are well served. Nexgel's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nexgel's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Adam Levy, President CEO | ||
| David Stefansky, Ex Director | ||
| Adam III, Chief Officer | ||
| Gregory Robb, Vice Operations |
Nexgel Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nexgel a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.23 | ||||
| Profit Margin | (0.68) % | ||||
| Operating Margin | (0.73) % | ||||
| Current Valuation | 24.74 M | ||||
| Shares Outstanding | 6.79 M | ||||
| Shares Owned By Insiders | 20.09 % | ||||
| Shares Owned By Institutions | 2.95 % | ||||
| Number Of Shares Shorted | 104.81 K | ||||
| Price To Book | 4.81 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nexgel Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nexgel. If investors know Nexgel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nexgel listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.59) | Revenue Per Share 0.846 | Quarterly Revenue Growth 0.234 | Return On Assets (0.23) | Return On Equity (0.64) |
The market value of Nexgel Inc is measured differently than its book value, which is the value of Nexgel that is recorded on the company's balance sheet. Investors also form their own opinion of Nexgel's value that differs from its market value or its book value, called intrinsic value, which is Nexgel's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nexgel's market value can be influenced by many factors that don't directly affect Nexgel's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nexgel's value and its price as these two are different measures arrived at by different means. Investors typically determine if Nexgel is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nexgel's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.